2m 2m 2m 2m 2m 2m 2m
Inhibrx Bio (INBX)
NASDAQ
$95.17+$1.87 (+2.00%)
Price as of Jun 23, 2026 11:43 AM EDT- $1.4BMarket Cap
- 540.80%1-Year Change
- BiotechnologyIndustry
Inhibrx Bio (INBX)
$95.17+$1.87 (+2.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 1.3M +550.00% | 200,000 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 1.3M +550.00% | 200,000 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -113.0M -44.52% | -203.7M N/A | |
Depreciation and Amortization Expense | 2.5M +8.67% | 2.3M N/A | |
Total Operating Expenses | 136.3M -58.89% | 331.6M N/A | |
Operating Profit | -135.0M -59.26% | -331.4M N/A | |
Interest Income | 7.5M -31.00% | 10.9M N/A | |
Interest Expense | -12.2M -9.63% | -13.5M N/A | |
Interest Income and Expense and Net | -4.7M +81.68% | -2.6M N/A | |
Total Nonoperating Income and Expense | -5.0M -100.25% | 2.0B N/A | |
Income before Taxes | -140.1M -108.30% | 1.7B N/A | |
Income Taxes | 2,000 0.00% | 2,000 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -140.1M -108.30% | 1.7B N/A | |
Net Income from Continuing Operations Applicable to Common | -140.1M -108.30% | 1.7B N/A | |
Basic EPS and Net Income | -9.04 -107.93% | 114.01 N/A | |
Diluted EPS and Net Income | -9.04 -108.03% | 112.62 N/A | |
Basic Weighted Average Shares | 15.5M +4.63% | 14.8M N/A | |
Diluted Weighted Average Shares | 15.5M +3.36% | 15.0M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 124.2M -18.60% | 152.6M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 124.2M -18.60% | 152.6M N/A | |
Total Current Assets | 132.8M -17.19% | 160.4M N/A | |
Accumulated Depreciation | 11.1M +25.05% | 8.9M N/A | |
Property and Plant and Equipment and Net | 3.7M -39.79% | 6.2M N/A | |
Total Long-Term Assets | 4.4M -35.91% | 6.8M N/A | |
Total Assets | 146.5M -18.97% | 180.8M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 33.8M -17.02% | 40.7M N/A | |
Total Long-Term Debt | 100.6M N/A | 0 N/A | |
Total Long-Term Liabilities | 104.7M +1,522.28% | 6.5M N/A | |
Total Liabilities | 138.5M +193.51% | 47.2M N/A | |
Retained Earnings | -246.2M +131.96% | -106.1M N/A | |
Total Stockholders Equity | 8.0M -94.02% | 133.6M N/A | |
Total Shares Outstanding | 14.6M +0.70% | 14.5M N/A | |
Cash Flow | |||
Cash from Operating Activities | -129.8M -33.24% | -194.4M N/A | |
Capital Expenditures | 31,000 -98.81% | 2.6M N/A | |
Cash from Investing Activities | -28,000 -98.92% | -2.6M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 101.4M +41.53% | 71.7M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | -10,386.54% N/A | N/A N/A | |
Return on Assets | -85.60% N/A | N/A N/A | |
Return on Equity | -197.85% N/A | N/A N/A | |
Revenue Growth | 550.00% N/A | N/A N/A | |
Current Ratio | 3.93 N/A | N/A N/A | |
Cash Ratio | 3.68 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow